Navigation Links
Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony

BEDFORD, Mass., Oct. 1, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced that Jack W. Cumming, Hologic's President and Chief Executive Officer, will preside over the NASDAQ Stock Market Opening Bell Ceremony marking the start of a month long effort to raise awareness of breast cancer and the importance of breast cancer screening. This is the eighth year that Hologic has been selected to participate in the NASDAQ opening bell ceremonies celebrating the start of Breast Cancer Awareness Month.

In his opening remarks, Mr. Cumming will focus on the value of Hologic's 3D mammography (breast tomosynthesis) in finding more invasive cancers and decreasing unnecessary recalls.Hologic's 3D Mammography Technology3D mammography (breast tomosynthesis) technology detects invasive cancers earlier when the disease is easiest to treat. Unlike conventional 2D mammography where the presence of overlapping breast tissue can make it more difficult to detect cancer, Hologic's 3D mammography technology is designed to allow doctors to see the breast more clearly, particularly for women with dense breasts.  As a result, fewer women are called back for additional testing due to false positive results. Large clinical studies in Europe and the U.S. report that Hologic's 3D mammography technology significantly reduces recall rates while simultaneously improving cancer detection.

  • Clinical research shows that the Hologic 3D mammogram finds 40% more invasive cancers than conventional 2D mammography.
  • Clearer, more detailed images from the Hologic 3D mammogram give doctors the confidence to significantly reduce recall rates by up to 40%, minimizing the inconvenience, cost and anxiety that women feel when asked to return for unnecessary follow-up tests.
  • Hologic is the only manufacturer to receive FDA approval for 3D mammography and is the largest breast tomosynthesis vendor worldwide. More than 3 million women will be screened this year with this groundbreaking technology.

    Webcast Information:The Hologic NASDAQ Stock Market Opening Bell Ceremony will be aired live at (access this by clicking on the MarketSite live webcam) and will also be aired with closed captioning on the NASDAQ MarketSite Tower in Times Square. A video of the Opening Bell ceremony will be archived for one year on the NASDAQ site.

    About Hologic, Inc.:Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit

    Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

    Forward-Looking Statement Disclaimer:This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic digital mammography systems. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

    Investor and Media Contacts:Deborah R. Gordon

    Marianne McMorrowVice President, Investor Relations

    Global PR and Advertising Publicist (781) 999-7716


    marianne.mcmorrow@hologic.comAl Kildani Senior Director, Investor Relations (858) 410-8653 

    SOURCE Hologic, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Hologic to Present at Two Upcoming Investor Conferences
    2. Hologic Announces Third Quarter Fiscal 2013 Operating Results
    3. Hologic Announces Completion of Term Loan B Repricing
    4. FDA Clears Hologics Single Energy Femur Exam to Visualize Features Associated with Developing Atypical Femur Fractures on a DXA Platform
    6. Hologic Appoints Jack W. Cumming President and Chief Executive Officer
    7. Commercial Release of 3D (Breast Tomosynthesis) Biopsy Option Strengthens Hologics Position as Provider of the Nations Most Comprehensive Portfolio of Interventional Breast Health Solutions
    8. Quest Diagnostics and Hologic Form Strategic Alliance to Improve Womens Health
    9. Hologic riceve lapprovazione FDA per una nuova soluzione di mammografia 3D (tomosintesi al seno) a bassa dose per lo screening del tumore al seno
    10. Hologic erhält FDA-Zulassung für eine neue niedrigdosierte 3D-Mammographie-Lösung (Brust-Tomosynthese) für Brustkrebs-Screening
    11. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
    Post Your Comments:
    (Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
    (Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
    (Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... It’s ... has a tattoo — a number even greater among Millennials (a whopping one in ... are more and more people who are dissatisfied with their ink. In fact, ...
    (Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
    (Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
    (Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
    Breaking Medicine News(10 mins):